Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 6/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6776019 | 0.78 | CHRM1 (0.64) | CHRM1 | |
| SCHEMBL13170185 | 0.70 | CHRM1 (0.53) | CHRM1 | |
| SCHEMBL28062125 | 0.70 | CHRM1 (0.54) | CHRM1 | |
| SCHEMBL31103576 | 0.70 | CHRM1 (0.54) | CHRM1 | |
| SCHEMBL28828294 | 0.70 | CHRM1 (0.54) | CHRM1 | |
| SCHEMBL28062102 | 0.68 | CHRM1 (0.52) | CHRM1 | |
| SCHEMBL6783767 | 0.68 | CHRM1 (0.51) | CHRM1 | |
| SCHEMBL6776793 | 0.66 | CHRM1 (0.49) | CHRM1CHRM2CHRM3CHRM4CHRM5 | |
| SCHEMBL6777276 | 0.66 | CHRM1 (0.49) | CHRM1 | |
| SCHEMBL6778182 | 0.65 | CHRM1 (0.48) | CHRM1CHRM2CHRM3CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6759419-B2 | NOOTROPIC AGENTS; BRAIN DISORDERS; ALZHEIMER'S DISEASE | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2004-07-06 | — | — | US | claimed |
| US-20030114491-A1 | Pyrrolidinone derivatives, their preparation and pharmaceutical composition comprising the same | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2003-06-19 | — | — | US | claimed |
| US-6759419-B2 | NOOTROPIC AGENTS; BRAIN DISORDERS; ALZHEIMER'S DISEASE | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2004-07-06 | — | — | US | disclosed |
| US-20030114491-A1 | Pyrrolidinone derivatives, their preparation and pharmaceutical composition comprising the same | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2003-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114491-A1 | Pyrrolidinone derivatives, their preparation and pharmaceutical composition comprising the same | CHRM1, CHRNA5, CHRNA7 | CHRM1 1/4885CHRM2 4/4885CHRM3 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.